Descriptive Observational Study ALK-2016-CPHG

CHARACTERISTICS OF ADULT PATIENTS TREATED WITH CRIZOTINIB FOR ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) WITH ALK GENE REARRANGEMENT OR ROS1 GENE REARRANGEMENT IN GENERAL HOSPITALS.

Descriptive Observational Study.

Characteristics Of ALK-positive and ROS1-positive Adults Patients Non-Small Cell Lung Cancer (NSCLC) Treated With Crizotinib Within General Hospitals

Describe the characteristics of patients treated with crizotinib Describe efficacy, safety, observance and QoL.

Inclusion criteria

• Age ≥ 18 years
• Locally advanced or metastatic NSCLC
• Patient ALK gene rearrangement or ROS1 gene rearrangement
• Patient having initiated in the previous 3 months or patient initiating crizotinib treatment regardless of the line of treatment
• Patient followed up by a physician in a hospital pulmonary medicine department
• Subject of reproductive age, using an effective method of contraception
• Patient informed verbally and in writing on the study and having consented to his/her personal data being collected within the scope of the study.

Non-inclusion criteria

• Patient included within the scope of an interventional therapeutic trial
• Patient not presenting with ALK gene rearrangement or ROS1 gene rearrangement
• Patient not available for follow-up throughout the duration of the study
• Patient deemed to be incapable of responding to the study questions for linguistic, cognitive or organisational reasons.